Acorda Therapeutics, Inc. logo

Acorda Therapeutics, Inc. Share Price (NASDAQ: ACOR)

▲

-0.66

(-100%)

Last updated on

Bell Icon

The stock has been delisted from the stock exchange on 11 Apr 2024

Check the interactive Acorda Therapeutics, Inc. Stock chart to analyse performance

Acorda Therapeutics, Inc. Key Stats

Check Acorda Therapeutics, Inc. key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$0.661
Open
$0.7838
Market Capitalization
$1.1M
Today's Volume
$414.1K
Revenue TTM
$111.1M
EBITDA
$11.5M
Earnings Per Share (EPS)
$2.61
PE Ratio
0.34
Profit Margin
-14.36%
Quarterly Earnings Growth YOY
5.87%
Return On Equity TTM
-23.68%

Global Institutional Holdings in Acorda Therapeutics, Inc.

  • Name

    Holdings %

  • Davidson Kempner Capital Management LP

    4.44%

  • Renaissance Technologies Corp

    3.68%

  • Acadian Asset Management LLC

    2.71%

  • Vanguard Group Inc

    0.86%

  • BlackRock Inc

    0.53%

  • Wells Fargo & Co

    0.30%

Analyst Recommendation on Acorda Therapeutics, Inc. Stock

Rating
Trend

Buy

    100%Buy

    0%Hold

    0%Sell

Based on 1 Wall street analysts offering stock ratings for Acorda Therapeutics, Inc.(by analysts ranked 0 to 5 stars)

About Acorda Therapeutics, Inc.

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.
Organization
Acorda Therapeutics, Inc.
Employees
111
CEO
Dr. Ron Cohen M.D.
Industry
Health Technology

Important FAQs about investing in ACOR Stock from India :

What is Acorda Therapeutics, Inc. share price today?

Acorda Therapeutics, Inc. share price today is as on at the close of the market. Acorda Therapeutics, Inc. share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for Acorda Therapeutics, Inc. share?

Acorda Therapeutics, Inc. share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. Acorda Therapeutics, Inc. stock price today i.e. is closed at , lower by 100% versus the 52 week high.

How to invest in Acorda Therapeutics, Inc. Stock (ACOR) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Acorda Therapeutics, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Acorda Therapeutics, Inc. Shares .

What is the minimum amount required to buy Acorda Therapeutics, Inc. Stock (ACOR) from India?

Indian investors can start investing in Acorda Therapeutics, Inc. (ACOR) shares with as little as ₹88.0338 or $1 (as of September 17, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹880.34 in Acorda Therapeutics, Inc. stock (as per the Rupee-Dollar exchange rate as on September 17, 2025). Learn more about fractional shares .

What are the returns that Acorda Therapeutics, Inc. has given to Indian investors in the last 5 years?

Acorda Therapeutics, Inc. stock has given 0.0% share price returns and 19.69% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?